FDA approves first drug to target the root cause of sickle cell disease 02-Dec-2019 By Vassia Barba Global Blood Therapeutics receives approval for Oxbryta, making it the first approved drug product that targets the root cause of sickle cell disease.
Lovelace, Exemplar to work on Sickle Cell Disease model under NIH contract 22-Jul-2019 By Vassia Barba Lovelace’s support and the inclusion in a $20m NIH contract enable Exemplar to continue the development of a porcine animal model for Sickle Cell Disease research.
Licensing agreement for distribution of first sickle-cell treatment approved in 20 years 10-Oct-2018 By Maggie Lynch Emmaus signed a distribution agreement with Cardinal Health to make Emmaus’ sickle-cell anemia treatment more readily available in the U.S.